Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Public ClinicalTrials.gov record NCT01512979. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week, Randomized, Double-blind, Active-controlled, Parallel Group Trial to Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotherapy in Newly Diagnosed, Treatment-naïve, Uncontrolled Type 2 Diabetes Mellitus Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this trial is to determine whether a initial combination of linagliptin and metformin compared to linagliptin alone for 24 weeks is effective in newly diagnosed, treatment-naïve patients with Type 2 Diabetes.
Study identification
- NCT ID
- NCT01512979
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 316 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2012 (Type not available)
- Primary completion
- Apr 2013 (Actual)
- Completion
- Apr 2013 (Actual)
- Last update posted
- May 20, 2014
2012 – 2013
United States locations
- U.S. sites
- 29
- U.S. states
- 14
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1218.83.11002 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1218.83.11036 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| 1218.83.11011 Boehringer Ingelheim Investigational Site | Chino | California | — | — |
| 1218.83.11001 Boehringer Ingelheim Investigational Site | Huntington Beach | California | — | — |
| 1218.83.11019 Boehringer Ingelheim Investigational Site | Huntington Park | California | — | — |
| 1218.83.11015 Boehringer Ingelheim Investigational Site | Lomita | California | — | — |
| 1218.83.11023 Boehringer Ingelheim Investigational Site | Norwalk | California | — | — |
| 1218.83.11014 Boehringer Ingelheim Investigational Site | Roseville | California | — | — |
| 1218.83.11031 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1218.83.11022 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1218.83.11025 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 1218.83.11033 Boehringer Ingelheim Investigational Site | Sanford | Florida | — | — |
| 1218.83.11029 Boehringer Ingelheim Investigational Site | Oakwood | Georgia | — | — |
| 1218.83.11026 Boehringer Ingelheim Investigational Site | Owensboro | Kentucky | — | — |
| 1218.83.11008 Boehringer Ingelheim Investigational Site | Elkton | Maryland | — | — |
| 1218.83.11027 Boehringer Ingelheim Investigational Site | Freemont | Nebraska | — | — |
| 1218.83.11005 Boehringer Ingelheim Investigational Site | Edison | New Jersey | — | — |
| 1218.83.11013 Boehringer Ingelheim Investigational Site | Jacksonville | North Carolina | — | — |
| 1218.83.11028 Boehringer Ingelheim Investigational Site | Salisbury | North Carolina | — | — |
| 1218.83.11009 Boehringer Ingelheim Investigational Site | Shelby | North Carolina | — | — |
| 1218.83.11003 Boehringer Ingelheim Investigational Site | Franklin | Ohio | — | — |
| 1218.83.11024 Boehringer Ingelheim Investigational Site | Gallipolis | Ohio | — | — |
| 1218.83.11018 Boehringer Ingelheim Investigational Site | Columbia | South Carolina | — | — |
| 1218.83.11004 Boehringer Ingelheim Investigational Site | Bristol | Tennessee | — | — |
| 1218.83.11017 Boehringer Ingelheim Investigational Site | Chattanooga | Tennessee | — | — |
| 1218.83.11032 Boehringer Ingelheim Investigational Site | Grand Prairie | Texas | — | — |
| 1218.83.11030 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1218.83.11034 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1218.83.11021 Boehringer Ingelheim Investigational Site | Tomball | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01512979, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2014 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01512979 live on ClinicalTrials.gov.